Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders

• Status: Completed
• Trial end date: 2016-10-06
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the feasibility of administering meclofenamic acid or pentosan polysulfate sodium as an adjunctive treatment to patients diagnosed with a psychotic disorder. Half of participants will receive meclofenamic acid, while the other half will receive polysulfate sodium.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Health Science Center, Houston
• Treatments: Meclofenamic Acid; Pentosan Sulfuric Polyester

Criteria

Inclusion Criteria:

• Diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar I disorder, delusional disorder, other specified schizophrenia spectrum and other psychotic disorders, unspecified schizophrenia spectrum and other psychotic disorders

• Negative pregnancy test in females of childbearing age

Exclusion Criteria:

• Urine drug screen positive for psychostimulants such as cocaine, amphetamines and ecstasy

• Any infection, neoplasm, autoimmune disease or other primary inflammatory condition (3) Previous diagnosis of intellectual disability or dementia

• Current treatment with heparin

• Use of or allergy to non-steroidal anti-inflammatory agent or pentosan polysulfate sodium

• Current or anticipated corticosteroid use

• History of peptic ulcer disease, gastro esophageal reflux disease, or gastrointestinal bleeding

• Those on warfarin or any anticoagulant

• Current treatment with lithium or asthma medication

• Individuals with pre-existing liver, cardiac, or kidney disease